Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25265151 | 0.82 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL15873299 | 0.82 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2692907 | 0.82 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL30301462 | 0.82 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL26633375 | 0.81 | EPHX1 (0.41) | EPHX1EPHX2 | |
| SCHEMBL26633380 | 0.81 | EPHX1 (0.41) | EPHX1EPHX2 | |
| SCHEMBL25263000 | 0.80 | CHRNB2 (0.39) | EPHX1CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL2186225 | 0.76 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL477253 | 0.76 | — | — | |
| SCHEMBL25189379 | 0.76 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-9260415-B2 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | GENENTECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | GENENTECH,INC. | 2014-01-02 | — | — | US | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | EPHX1 3870/4885CHRNB2 3970/4885CHRNA4 3753/4885 |
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | EPHX1 3922/4885CHRNB2 3202/4885CHRNA4 2869/4885 |
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | EPHX1 2352/4885CHRNB2 3335/4885CHRNA4 3921/4885 |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | BTK, TYK2, LCK | EPHX1 2247/4885CHRNB2 2844/4885CHRNA4 2708/4885 |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | EPHX1 1663/4885CHRNB2 3164/4885CHRNA4 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.